Byoung C. Cho
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 448 publications
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026
A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib.
Journal: Future oncology (London, England)
Published: July 16, 2026
Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
Journal: Nature medicine
Published: June 29, 2026
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 26, 2026
Structural basis and preclinical efficacy of MG1124, a novel CEACAM1-targeting antibody synergizing with PD-1 blockade.
Journal: Molecular cancer therapeutics
Published: May 10, 2026
Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 08, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 26, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 26, 2026
Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. Reply.
Journal: The New England journal of medicine
Published: February 25, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 20, 2026
Last Updated: 09/26/2026